{"commentary":{"count":38,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":18,"podcast":11,"x_thread":9},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04625270\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RAMP 201","nct_id":"NCT04625270","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ramp-201-nct04625270. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"RAMP 201","arms":[{"description":"To determine the optimal regimen, either avutometinib(VS-6766) monotherapy or avutometinib (VS-6766) in combination with defactinib, for subsequent evaluation for efficacy in the Expansion Phase (Part B)","label":"Part A","type":"EXPERIMENTAL"},{"description":"To determine the efficacy of the optimal regimen identified from Part A","label":"Part B","type":"EXPERIMENTAL"},{"description":"To evaluate additional efficacy parameters for the optimal regimen identified in Part A.","label":"Part C:","type":"EXPERIMENTAL"},{"description":"To evaluate additional efficacy parameters for a lower dose of avutometinib in combination with defactinib","label":"Part D","type":"EXPERIMENTAL"}],"collaborators":["European Network of Gynaecological Oncological Trial Groups (ENGOT)","GOG Foundation"],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Low Grade Ovarian Serous Adenocarcinoma","Ovarian Cancer"],"enrollment":{"count":225,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"avutometinib (VS-6766)","type":"DRUG"},{"name":"avutometinib (VS-6766) and defactinib","type":"DRUG"}],"last_update":"2025-01-29","lead_sponsor":"Verastem, Inc.","official_title":"A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2024-11-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part A: Determine optimal regimen of avutometinib (VS-6766) monotherapy or in combination with defactinib","timeFrame":"From start of treatment to confirmation of response; 24 weeks"},{"measure":"Part B: To determine the efficacy of the optimal regimen identified from Part A","timeFrame":"From start of treatment to confirmation of response; 24 weeks"},{"measure":"Part C: To evaluate additional efficacy parameters for the optimal regimen identified in Part A","timeFrame":"From start of treatment to confirmation of response; 24 weeks"},{"measure":"Part D:To evaluate additional efficacy parameters for a lower dose of avutometinib in combination with defactinib","timeFrame":"From start of treatment to confirmation of response; 24 weeks"}],"references":[{"citation":"Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, Prendergast E, Oaknin A, Ring K, Colombo N, Holloway RW, Rodrigues M, Chon HS, Gourley C, Santin AD, Thaker PH, Gennigens C, Newman G, Salinas E, Youssoufian H, Moore KN, Lustgarten S, O'Malley DM, Van Gorp T, Grisham RN. Efficacy and Safety of Avutometinib +/- Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol. 2025 Sep;43(25):2782-2792. doi: 10.1200/JCO-25-00112. Epub 2025 Jul 11.","pmid":"40644648","type":"DERIVED"},{"citation":"McNamara B, Demirkiran C, Hartwich TMP, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz PE, Coma S, Pachter JA, Santin AD. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecol Oncol. 2024 Apr;183:133-140. doi: 10.1016/j.ygyno.2024.01.028. Epub 2024 Mar 15.","pmid":"38493021","type":"DERIVED"}],"start_date":{"date":"2020-12-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation","url":"https://clinicaltrials.gov/study/NCT04625270"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ramp-201-nct04625270"}